108 related articles for article (PubMed ID: 8550242)
1. Detection of p53 gene alteration in renal-cell cancer by micropreparation techniques of tumor specimens.
Kuczyk MA; Serth J; Bokemeyer C; Jonassen J; Arndt H; Paeslack U; Werner M; Tan HK; Jonas U
Int J Cancer; 1995 Dec; 64(6):399-406. PubMed ID: 8550242
[TBL] [Abstract][Full Text] [Related]
2. Infrequent p53 gene mutations and lack of p53 protein expression in clear cell sarcoma of the kidney: immunohistochemical study and mutation analysis of p53 in renal tumors of unfavorable prognosis.
Hsueh C; Wang H; Gonzalez-Crussi F; Lin JN; Hung IJ; Yang CP; Jiang TH
Mod Pathol; 2002 Jun; 15(6):606-10. PubMed ID: 12065773
[TBL] [Abstract][Full Text] [Related]
3. Expression of p53 and bcl-2 in primary locally confined renal cell carcinomas: no evidence for prognostic significance.
Hofmockel G; Wittmann A; Dammrich J; Bassukas ID
Anticancer Res; 1996; 16(6B):3807-11. PubMed ID: 9042262
[TBL] [Abstract][Full Text] [Related]
4. The 72nd codon change of p53 in primary renal cell carcinoma was confirmed as a polymorphism among Japanese.
Kageyama Y; Yamamura Y; Oshima H; Ikawa Y
Eur Urol; 1997; 31(1):81-5. PubMed ID: 9032540
[TBL] [Abstract][Full Text] [Related]
5. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue.
Zigeuner R; Ratschek M; Rehak P; Schips L; Langner C
Urology; 2004 Apr; 63(4):651-5. PubMed ID: 15072872
[TBL] [Abstract][Full Text] [Related]
6. Association of immunohistochemical staining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma.
Uhlman DL; Nguyen PL; Manivel JC; Aeppli D; Resnick JM; Fraley EE; Zhang G; Niehans GA
J Natl Cancer Inst; 1994 Oct; 86(19):1470-5. PubMed ID: 8089867
[TBL] [Abstract][Full Text] [Related]
7. p53 and HER-2 alterations in renal cell carcinoma.
Zhang XH; Takenaka I; Sato C; Sakamoto H
Urology; 1997 Oct; 50(4):636-42. PubMed ID: 9338750
[TBL] [Abstract][Full Text] [Related]
8. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma.
Navone NM; Troncoso P; Pisters LL; Goodrow TL; Palmer JL; Nichols WW; von Eschenbach AC; Conti CJ
J Natl Cancer Inst; 1993 Oct; 85(20):1657-69. PubMed ID: 7692074
[TBL] [Abstract][Full Text] [Related]
9. Expression of CD44 protein in renal cell carcinomas: association with p53 expression.
Zolota V; Tsamandas AC; Melachrinou M; Batistatou A; Scopa C
Urol Oncol; 2002; 7(1):13-7. PubMed ID: 12474536
[TBL] [Abstract][Full Text] [Related]
10. P53 and MDM2 Over-expression and Five-year Survival of Kidney Cancer Patients Undergoing Radical Nephrectomy--Iranian Experience.
Abolhasani M; Salarinejad S; Asgari M
Asian Pac J Cancer Prev; 2015; 16(12):5043-7. PubMed ID: 26163638
[TBL] [Abstract][Full Text] [Related]
11. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer.
Esrig D; Spruck CH; Nichols PW; Chaiwun B; Steven K; Groshen S; Chen SC; Skinner DG; Jones PA; Cote RJ
Am J Pathol; 1993 Nov; 143(5):1389-97. PubMed ID: 7901994
[TBL] [Abstract][Full Text] [Related]
12. Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance.
Niwa K; Itoh M; Murase T; Morishita S; Itoh N; Mori H; Tamaya T
Br J Cancer; 1994 Dec; 70(6):1191-7. PubMed ID: 7981076
[TBL] [Abstract][Full Text] [Related]
13. Investigation of tumor suppressor genes apart from VHL on 3p by deletion mapping in sporadic clear cell renal cell carcinoma (cRCC).
Singh RB; Amare Kadam PS
Urol Oncol; 2013 Oct; 31(7):1333-42. PubMed ID: 21962529
[TBL] [Abstract][Full Text] [Related]
14. Allelic frequency of p53 gene codon 72 polymorphism in urologic cancers.
Wu WJ; Kakehi Y; Habuchi T; Kinoshita H; Ogawa O; Terachi T; Huang CH; Chiang CP; Yoshida O
Jpn J Cancer Res; 1995 Aug; 86(8):730-6. PubMed ID: 7559095
[TBL] [Abstract][Full Text] [Related]
15. Correlation of allelic loss of the P53 gene and tumor grade, stage, and malignant progression in bladder cancer.
Tsutsumi M; Sugano K; Yamaguchi K; Kakizoe T; Akaza H
Int J Urol; 1997 Jan; 4(1):74-8. PubMed ID: 9179671
[TBL] [Abstract][Full Text] [Related]
16. Infrequent involvement of p53 mutations and loss of heterozygosity of 17p in the tumorigenesis of renal cell carcinoma.
Uchida T; Wada C; Shitara T; Egawa S; Mashimo S; Koshiba K
J Urol; 1993 Oct; 150(4):1298-301. PubMed ID: 8103806
[TBL] [Abstract][Full Text] [Related]
17. Polymerase chain reaction-single strand conformation polymorphism analysis of the p53 gene in paraffin-embedded surgical material from human renal cell carcinomas.
Kikuchi Y; Kishi T; Suzuki M; Furusato M; Aizawa S
Virchows Arch; 1994; 424(3):229-33. PubMed ID: 8186888
[TBL] [Abstract][Full Text] [Related]
18. Allelic loss at TP53 is not related to p53 protein overexpression in primary human endometrial carcinomas.
Semczuk A; Marzec B; Skomra D; Roessner A; Cybulski M; Rechberger T; Schneider-Stock R
Oncology; 2005; 69(4):317-25. PubMed ID: 16293976
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance and expression of PUMA, MCL-1, and p53 in human renal cell carcinoma and para-carcinoma tissues.
Xia HB; Cui HW; Su L; Zhang ZH; Yang XY; Ning SQ; Su XL
Genet Mol Res; 2017 Jul; 16(3):. PubMed ID: 28692117
[TBL] [Abstract][Full Text] [Related]
20. Elevated content of p53 protein in the absence of p53 gene mutations as a possible prognostic marker for human renal cell tumors.
Chemeris G; Loktinov A; Rempel A; Schwarz M; Bannasch P
Virchows Arch; 1995; 426(6):563-9. PubMed ID: 7655736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
